Briobacept blocks circulating BLyS, thus inhibiting B cell activation and promoting B cell apoptosis[3].
Briobacept (100 μg/mouse; i.p.; for 5 d) inhibits basal NF-κB2 activation in wild-type mice[4].
Briobacept (100 μg/mouse; i.p.; 3 times per week for 5 weeks) inhibits p52 generation and development of spontaneous lupus-like disease in NZB/WF1 mice[4].
References:
[1]. Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2). Reumatol Clin. 2012 Sep-Oct;8(5):263-9.
[2]. Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22(33):3152-3154.
[3]. La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther. 2010 Nov;10(11):1555-61.
[4]. Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002 Oct;17(4):515-24.